The main purpose of this research is to evaluate how safe BLU-808 is and how well patients tolerate it. The study is designed for people whose hives are not well controlled with standard antihistamine medications. The research will be conducted in two parts – one focusing on patients with chronic inducible urticaria and another on those with chronic spontaneous urticaria.

During the study, which lasts 12 weeks, participants will take the study medication and have their symptoms monitored. The researchers will track any changes in the participants’ condition, including how the medication affects their hives and overall symptoms. They will also measure how the medication moves through the body and its effects on various biological markers.

The study aims to determine how well remibrutinib works in controlling urticaria symptoms compared to placebo. During the treatment, participants will also take standard medications including corticosteroids (anti-inflammatory medicines) and antihistamines (medications that help reduce allergic reactions). The study will last for 12 weeks, during which participants will need to regularly record their symptoms.

Throughout the study, doctors will monitor how well the treatment controls urticaria symptoms, particularly focusing on the most bothersome symptoms such as itching, pain, and burning sensations. They will also assess how the treatment affects participants’ quality of life and track any side effects that may occur. Neither the participants nor the doctors conducting the study will know who is receiving the actual medication and who is receiving placebo.

The purpose of this study is to evaluate how safe Briquilimab is and how well it works over a longer period. Participants in this study will have previously taken part in other trials sponsored by Jasper Therapeutics, the company behind Briquilimab. During the study, participants will receive regular injections of Briquilimab and will be monitored for any side effects or changes in their condition. The study will help researchers understand how Briquilimab affects the symptoms of Chronic Urticaria over time.

Throughout the study, participants will undergo regular check-ups and assessments to track their progress and any potential side effects. The study aims to provide valuable information on the long-term use of Briquilimab for managing Chronic Urticaria, contributing to the development of effective treatments for this persistent skin condition.

The purpose of the study is to determine if remibrutinib can help more people achieve a complete response, meaning their symptoms are fully controlled, compared to those taking a placebo. Participants in the study will take the medication orally, in the form of a film-coated tablet, over a period of 52 weeks. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo, to ensure unbiased results. There is also an open-label extension, which means that after the initial study period, all participants may have the opportunity to receive the actual medication.

Throughout the study, participants will be monitored for any changes in their symptoms and any side effects they may experience. The study aims to provide valuable information on the safety, effectiveness, and tolerability of remibrutinib for people with CINDU. This research could potentially lead to a new treatment option for those who struggle with this challenging condition.

Participants in the study will receive either Briquilimab or a placebo. The trial will monitor the participants for any side effects and changes in their condition. The study will also involve various tests to assess the response to the treatment, such as checking the temperature or friction level that triggers symptoms. The goal is to see if Briquilimab can help control the symptoms of Chronic Inducible Urticaria better than current treatments.

The trial will take place over a period of time, with regular visits to monitor the participants’ health and response to the treatment. The study will also measure how long it takes for the symptoms to improve or return after treatment. This research is important for finding new ways to help people with Chronic Inducible Urticaria who do not get enough relief from existing medications.